Your browser doesn't support javascript.
loading
Exploring the ATN classification system using brain morphology.
Heinzinger, Nils; Maass, Anne; Berron, David; Yakupov, Renat; Peters, Oliver; Fiebach, Jochen; Villringer, Kersten; Preis, Lukas; Priller, Josef; Spruth, Eike Jacob; Altenstein, Slawek; Schneider, Anja; Fliessbach, Klaus; Wiltfang, Jens; Bartels, Claudia; Jessen, Frank; Maier, Franziska; Glanz, Wenzel; Buerger, Katharina; Janowitz, Daniel; Perneczky, Robert; Rauchmann, Boris-Stephan; Teipel, Stefan; Killimann, Ingo; Göerß, Doreen; Laske, Christoph; Munk, Matthias H; Spottke, Annika; Roy, Nina; Heneka, Michael T; Brosseron, Frederic; Dobisch, Laura; Ewers, Michael; Dechent, Peter; Haynes, John Dylan; Scheffler, Klaus; Wolfsgruber, Steffen; Kleineidam, Luca; Schmid, Matthias; Berger, Moritz; Düzel, Emrah; Ziegler, Gabriel.
Afiliação
  • Heinzinger N; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany. nils.heinzinger@st.ovgu.de.
  • Maass A; Institute of Cognitive Neurology and Dementia Research (IKND), University Hospital Magdeburg, Otto-von-Guericke University, Leipziger Str. 44, 39120, Magdeburg, Germany. nils.heinzinger@st.ovgu.de.
  • Berron D; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
  • Yakupov R; Institute of Cognitive Neurology and Dementia Research (IKND), University Hospital Magdeburg, Otto-von-Guericke University, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Peters O; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
  • Fiebach J; Institute of Cognitive Neurology and Dementia Research (IKND), University Hospital Magdeburg, Otto-von-Guericke University, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Villringer K; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
  • Preis L; Institute of Cognitive Neurology and Dementia Research (IKND), University Hospital Magdeburg, Otto-von-Guericke University, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Priller J; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Spruth EJ; Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
  • Altenstein S; Center for Stroke Research Berlin, Charité-Universitätsmedizin, Berlin, Germany.
  • Schneider A; Center for Stroke Research Berlin, Charité-Universitätsmedizin, Berlin, Germany.
  • Fliessbach K; Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
  • Wiltfang J; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Bartels C; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany.
  • Jessen F; Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.
  • Maier F; University of Edinburgh and UK DRI, Edinburgh, UK.
  • Glanz W; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Buerger K; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany.
  • Janowitz D; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Perneczky R; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany.
  • Rauchmann BS; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Teipel S; Department of Neurodegenerative Diseases and Geriatric Psychiatry/Psychiatry, University of Bonn Medical Center, Bonn, Germany.
  • Killimann I; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Göerß D; Department of Neurodegenerative Diseases and Geriatric Psychiatry/Psychiatry, University of Bonn Medical Center, Bonn, Germany.
  • Laske C; German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
  • Munk MH; Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, University of Göttingen, Göttingen, Germany.
  • Spottke A; Department of Medical Sciences, Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), University of Aveiro, Aveiro, Portugal.
  • Roy N; Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, University of Göttingen, Göttingen, Germany.
  • Heneka MT; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Brosseron F; Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany.
  • Dobisch L; Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
  • Ewers M; Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany.
  • Dechent P; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
  • Haynes JD; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Scheffler K; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
  • Wolfsgruber S; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
  • Kleineidam L; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Schmid M; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
  • Berger M; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
  • Düzel E; Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, UK.
  • Ziegler G; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
Alzheimers Res Ther ; 15(1): 50, 2023 03 13.
Article em En | MEDLINE | ID: mdl-36915139
BACKGROUND: The NIA-AA proposed amyloid-tau-neurodegeneration (ATN) as a classification system for AD biomarkers. The amyloid cascade hypothesis (ACH) implies a sequence across ATN groups that patients might undergo during transition from healthy towards AD: A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+. Here we assess the evidence for monotonic brain volume decline for this particular (amyloid-conversion first, tau-conversion second, N-conversion last) and alternative progressions using voxel-based morphometry (VBM) in a large cross-sectional MRI cohort. METHODS: We used baseline data of the DELCODE cohort of 437 subjects (127 controls, 168 SCD, 87 MCI, 55 AD patients) which underwent lumbar puncture, MRI scanning, and neuropsychological assessment. ATN classification was performed using CSF-Aß42/Aß40 (A+/-), CSF phospho-tau (T+/-), and adjusted hippocampal volume or CSF total-tau (N+/-). We compared voxel-wise model evidence for monotonic decline of gray matter volume across various sequences over ATN groups using the Bayesian Information Criterion (including also ROIs of Braak stages). First, face validity of the ACH transition sequence A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+ was compared against biologically less plausible (permuted) sequences among AD continuum ATN groups. Second, we evaluated evidence for 6 monotonic brain volume progressions from A-T-N- towards A+T+N+ including also non-AD continuum ATN groups. RESULTS: The ACH-based progression A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+ was consistent with cognitive decline and clinical diagnosis. Using hippocampal volume for operationalization of neurodegeneration (N), ACH was most evident in 9% of gray matter predominantly in the medial temporal lobe. Many cortical regions suggested alternative non-monotonic volume progressions over ACH progression groups, which is compatible with an early amyloid-related tissue expansion or sampling effects, e.g., due to brain reserve. Volume decline in 65% of gray matter was consistent with a progression where A status converts before T or N status (i.e., ACH/ANT) when compared to alternative sequences (TAN/TNA/NAT/NTA). Brain regions earlier affected by tau tangle deposition (Braak stage I-IV, MTL, limbic system) present stronger evidence for volume decline than late Braak stage ROIs (V/VI, cortical regions). Similar findings were observed when using CSF total-tau for N instead. CONCLUSION: Using the ATN classification system, early amyloid status conversion (before tau and neurodegeneration) is associated with brain volume loss observed during AD progression. The ATN system and the ACH are compatible with monotonic progression of MTL atrophy. TRIAL REGISTRATION: DRKS00007966, 04/05/2015, retrospectively registered.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Alzheimers Res Ther Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Alzheimers Res Ther Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha